Weifang Shengtai Medicine Co., Ltd.: A single kernel of corn connects to a golden industrial chain in modern agriculture.
Weifang Shengtai Medicine Co., Ltd.: A single kernel of corn connects to a golden industrial chain in modern agriculture.

This is the only comprehensive agricultural open development experimental zone in China. Adhering to a global perspective and international standards, and leveraging Shandong's advantages and Weifang's unique characteristics, it provides a new model for agricultural opening-up and new experiences for modern agricultural development.In the fertile fields of Changle, Weifang, the once ordinary corn crop is undergoing a remarkable transformation from field raw material to high-value-added products, thanks to the open development platform of the Weifang National Agricultural Comprehensive Zone and the full-chain layout of Shengtai Pharmaceutical. This is writing a vivid chapter in the industrialization and internationalization of agriculture. After decades of dedicated development, Shengtai Pharmaceutical, as a leading enterprise in agricultural industrialization, has rooted itself in the corn deep-processing sector. With a full-chain approach, it has reshaped the value of corn, building a complete industrial system from raw material control to end products, from technology research and development to global trade. This allows corn to achieve value transformation through biotechnology, becoming a core high-quality raw material in multiple fields such as pharmaceuticals and food.In the R&D center laboratory of Weifang Shengtai Pharmaceutical, researchers are focused on testing the dissolution parameters of glucose raw materials. "By optimizing the crystallization temperature and stirring rate, the product's bulk density and crystallization yield have been significantly improved," explained Li Hailiang, director of the company's R&D center. This technological breakthrough not only provides higher-quality raw materials for downstream food and pharmaceutical industries but also allows the company to maintain its leading market share in pharmaceutical glucose. From the field to the factory, from R&D to the market, Shengtai Pharmaceutical consistently adheres to the highest international standards in quality control, creating a diversified product portfolio including starch, glucose, maltodextrin, and crystalline fructose. Currently, its products cover 30 provinces, municipalities, and autonomous regions in China and are exported to over 70 countries and regions worldwide.Starting with a single kernel of corn, Shengtai Pharmaceutical continues to empower industrial upgrading through technological innovation and expand into the global market with an open vision. On the development platform of the Weifang National Agricultural Comprehensive Zone, it is constantly exploring new paths for the intensive processing of modern agriculture, unleashing the great potential of small corn kernels and continuously contributing to the high-quality development of modern agriculture.

Weifang Shengtai Medicine Co., Ltd. Shengtai Medicine is deeply committed to upgrading its glucose processing technology.
Weifang Shengtai Medicine Co., Ltd. Shengtai Medicine is deeply committed to upgrading its glucose processing technology.

Weifang Shengtai Medicine Co., Ltd., a hidden champion in the domestic glucose raw material industry with many years of experience, has always prioritized the iterative upgrading of glucose production processes in its R&D, continuously tackling technological challenges with stringent standards in the high-end pharmaceutical and food raw material market.In the company's R&D center laboratory, the R&D team is conducting refined experiments focusing on the core aspects of glucose production. Researchers are concentrating on testing the solubility parameters of glucose raw materials, constantly refining the details of the production process. Li Hailiang, director of the company's R&D center, explained, "By optimizing the crystallization temperature and stirring rate, the product's bulk density and crystallization yield have been significantly improved." This technological breakthrough not only further solidifies the product's quality barrier, providing higher purity and more stable high-quality raw materials for downstream food and pharmaceutical fields, but also propels the company's domestic market share of pharmaceutical glucose to nearly 60%, firmly establishing its leading position in the industry. Currently, Shengtai Pharmaceutical's starch and glucose series products cover 30 provinces, autonomous regions, and municipalities in China, and are exported to more than 70 countries and regions worldwide, making it a benchmark enterprise for Chinese glucose raw material exports.